Abstract
The metabolism of tumor cells (tumor metabolome) is characterized by a high concentration of glycolytic enzymes including pyruvate kinase isoenzyme type M2 (M2-PK), a high glutaminolytic capacity, high fructose 1,6-bisphosphate (FBP) levels and a low (ATP+GTP):(CTP+UTP) ratio. The sequence of events required for the establishment of the tumor metabolome is presently unknown. In non-transformed rat kidney (NRK) cells we observed a high glutaminolytic flux rate and a low (ATP+GTP):(CTP+UTP) ratio, whereas FBP levels and M2-PK activity are still extremely low. After stable expression of oncogenic ras in NRK cells a strong upregulation of FBP levels and of M2-PK activity was observed. Elevated FBP levels induce a tetramerization of M2-PK and its migration into the glycolytic enzyme complex. AMP levels increase whereas UTP and CTP levels strongly decrease. Thus, ras expression completes the glycolytic part of tumor metabolism leading to the inhibition of nucleic acid synthesis and cell proliferation. The HPV-16 E7 oncoprotein, which cooperates with ras in cell transformation, directly binds to M2-PK, induces its dimerization and restores nucleic acid synthesis as well as cell proliferation. Apparently, the combination of the different metabolic effects of ras and E7 constructs the perfect tumor metabolome as generally found in tumor cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aon MA, Monaco ME, Cortassa S . 1995 Exp. Cell Res. 217: 42–51
Bedell MA, Jones KH, Laimins LA . 1987 J. Virol. 61: 3635–3640
Board M, Humm S, Newsholme EA . 1990 Biochem. J. 265: 503–509
Boros LG, Puigjaner J, Cascante M, Lee W-N, Brandes JL, Bassilian S, Yusuf FI, Williams RD, Muscarella P, Melvin WS, Schirmer WJ . 1997 Cancer Res. 57: 4242–4248
Boros LG, Torday JS, Lim S, Bassilian S, Cascante M, Lee W-NP . 2000 Cancer Res. 60: 1183–1185
Brazill DT, Thorner J, Martin GS . 1997 J. Bacteriol. 179: 4415–4418
Carmeliet P, Dor Y, Herbert J-M, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshet E . 1998 Nature 394: 485–490
Cascante M, Centelles JJ, Veech RL, Lee W-NP, Boros LG . 2000 Nutr. Cancer 36: 150–154
Chopade BA, Shankar S, Sundin GW, Mukhopadhyay S, Chakrabarty AM . 1997 J. Bacteriol. 179: 2181–2188
Crook T, Morgenstern JP, Crawford L, Banks L . 1989 EMBO J. 8: 513–519
Dang CV, Semenza GL . 1999 TIBS 24: 68–72
Downes CS, Bachrati CZ, Devlin SJ, Tommasino M, Cutts TJR, Watson JV, Rasko I, Johnson RT . 2000 J. Cell Sci. 113: 1089–1096
Dupriez VJ, Darville MI, Antoine IV, Gegonne A, Ghysdael J, Rousseau GG . 1993 Proc. Natl. Acad. Sci. USA 90: 8224–8228
Eigenbrodt E, Fister P, Reinacher M . 1985 Regulation of Carbohydrate Metabolism. Beitner R. (ed.) CRC Press Inc.: Boca Raton, Fl pp. 141–179
Eigenbrodt E, Kallinowski F, Ott M, Mazurek S, Vaupel P . 1998a Anticancer Res. 18: 3267–3274
Eigenbrodt E, Mazurek S, Friis RR . 1998b Cell Growth and Oncogenesis. Bannasch P, Kanduc D, Papa S and Tager JM. (eds). Birkhäuser Verlag: Basel pp. 15–30
Eigenbrodt E, Reinacher M, Scheefers-Borchel U, Scheefers H, Friis R . 1992 Crit. Rev. Oncol. 3: 91–115
Glass-Marmor L, Beitner R . 1999 Eur. J. Pharmacol. 370: 195–199
Glossmann H, Presek P, Eigenbrodt E . 1981 Mol. Cell. Endocrinol. 23: 49–63
Gregory SH, Kumari HL, Lakshimi MV, Bose SK . 1976 Arch. Biochem. Biophys. 175: 644–653
Henderson JF, Scott FW . 1981 Pharma. Ther. 8: 539–571
Hunting D, Hordern J, Henderson JF . 1981 Can. J. Biochem. 59: 821–829
Inouye S, Yamada Y, Miura K, Suzuki H, Kawata K, Shinoda K, Nakazawa A . 1999 Biochem. Biophys. Res. Commun. 254: 618–622
Jackson RC, Lui MS, Boritzki TJ, Morris HP, Weber G . 1980 Cancer Res. 40: 1286–1291
Kim CY, Tsai MH, Osmanian C, Graeber TG, Lee JE, Giffard RG, DiPaolo JA, Peehl DM, Giaccia AJ . 1997 Cancer Res. 57: 4200–4204
Kohler C, Gahm A, Noma T, Nakazawa A, Orrenius S, Zhivotovsky B . 1999 FEBS Lett. 447: 10–12
Kole HK, Resnick RJ, van Doren M, Racker E . 1991 Arch. Biochem. Biophys. 286: 586–590
Linke SP, Clarkin KC, Di Leonardo A, Tsou A, Wahl GM . 1996 Genes. Dev. 10: 934–947
Mazurek S, Boschek CB, Eigenbrodt E . 1997a J. Bioenerg. Biomemb. 29: 315–330
Mazurek S, Eigenbrodt E, Failing K, Steinberg P . 1999 J. Cell. Physiol. 181: 136–146
Mazurek S, Grimm H, Boschek CB, Vaupel P, Eigenbrodt E . 2001a Br. J. Nutr In press
Mazurek S, Grimm H, Wilker S, Leib S, Eigenbrodt E . 1998 Anticancer Res. 18: 3275–3282
Mazurek S, Hugo F, Failing K, Eigenbrodt E . 1996 J. Cell. Physiol. 167: 238–250
Mazurek S, Michel A, Eigenbrodt E . 1997b J. Biol. Chem. 272: 4941–4952
Mazurek S, Zwerschke W, Jansen-Dürr P, Eigenbrodt E . 2001b Biochem. J. 356: 247–256
Moyer JD, Smith PA, Levy EJ, Handschumacher RE . 1982 Cancer Res. 42: 4525–4531
Nagy E, Henics T, Eckert M, Miseta A, Lightowlers RN, Kellermayer M . 2000 Biochem. Biophys. Res. Commun. 275: 253–260
Nagy E, Rigby FC . 1995 J. Biol. Chem. 270: 2755–2763
Noma T, Adachi N, Nakazawa A . 1999 Biochem. Biophys. Res. Commun. 264: 990–997
Penso J, Beitner R . 1998 Eur. J. Pharmacol. 342: 113–117
Presek P, Reinacher M, Eigenbrodt E . 1988 FEBS Lett. 242: 194–198
Reshkin SJ, Bellizzi A, Caldeira S, Albarani V, Malanchi I, Poignee M, Alunni-Fabbroni M, Casavola V, Tommasino M . 2000 FASEB J. 14: 2185–2197
Ryll T, Wagner R . 1992 Biotechnol. Bioeng. 40: 934–946
Schäfer D, Hamm-Künzelmann B, Brand K . 1997 FEBS Lett. 417: 325–328
Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW . 1997 Cell 88: 593–602
Shim H, Chun YS, Lewis BC, Dang CV . 1998 Proc. Natl. Acad. Sci. USA 95: 1511–1516
Shim H, Dolde C, Lewis BC, Wu C-S, Dang G, Jungmann RA, Dalla-Favera R, Dang CV . 1997 Proc. Natl. Acad. Sci. USA 94: 6658–6663
Thomas S, Fell DA . 1998 Eur. J. Biochem. 258: 956–967
Weber G, Stubbs M, Morris HP . 1971 Cancer Res. 31: 2177–2183
Zwerschke W, Jansen-Dürr P . 2000 Adv. Cancer Res. 78: 1–29
Zwerschke W, Mazurek S, Massimi P, Banks, Eigenbrodt E, Jansen-Dürr P . 1999 Proc. Natl. Acad. Sci. USA 96: 1291–1296
Acknowledgements
This work was supported by the Land Hessen (S Mazurek: HSP III), the Deutsche Forschungsgemeinschaft (S Mazurek: Ma 1760 1-2 and 2-1) and in P Jansen-Dürr's laboratory by the Austrian Science Funds (FWF), the European Union (Biomed 2) and the Austrian Ministry of Science and Traffic.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mazurek, S., Zwerschke, W., Jansen-Dürr, P. et al. Metabolic cooperation between different oncogenes during cell transformation: interaction between activated ras and HPV-16 E7. Oncogene 20, 6891–6898 (2001). https://doi.org/10.1038/sj.onc.1204792
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204792
Keywords
This article is cited by
-
Fructose-1,6-bisphosphate couples glycolytic flux to activation of Ras
Nature Communications (2017)
-
Oxidative Dimerization of PHD2 is Responsible for its Inactivation and Contributes to Metabolic Reprogramming via HIF-1α Activation
Scientific Reports (2016)
-
Metabolic reprogramming: a hallmark of viral oncogenesis
Oncogene (2016)
-
Metabolic signatures of Besnoitia besnoiti-infected endothelial host cells and blockage of key metabolic pathways indicate high glycolytic and glutaminolytic needs of the parasite
Parasitology Research (2016)
-
Metabolomic changes during cellular transformation monitored by metabolite–metabolite correlation analysis and correlated with gene expression
Metabolomics (2015)